Gentian Diagnostics

[Savepig]

Det var jo også to meldinger til nylig:

18.12.25: Gentian Diagnostics: Update on NT-proBNP

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today provided an update on the development of its turbidimetric NT-proBNP assay, which remains the company’s highest-priority pipeline project.

Throughout the fourth quarter of 2025, Gentian made solid progress in advancing the assay toward final product verification. Continued refinement of the calibration approach has led to further improvements in the assay’s analytical performance. To ensure a high-quality and robust product, the company has prioritised additional refinement work ahead of the research-use-only (RUO) introduction, leading to a minor delay compared with earlier expectations. Clinical performance evaluations with external partners are ongoing, and the company expects to provide an update on the RUO product during the first quarter of 2026.

Gentian Diagnostics continues to target the launch of a CE-marked NT-proBNP assay in the fourth quarter of 2026, in line with previous communication.

07.01.26 Gentian Diagnostics announces exclusive partnership for the development of a novel diagnostic assay with a leading global IVD company

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of high-quality diagnostic assays, announces that it has entered into an exclusive cooperation agreement with a leading globs, 7 January 2026al diagnostics company for the development of a novel assay to be integrated on one of the most widely used clinical chemistry analyser platforms in the world.

Under the agreement, Gentian is responsible for assay development and will also undertake manufacturing upon commercialisation.

In line with the partner’s strategic communications policy, the identity of the biomarker and its specific diagnostic application remain undisclosed. The project is well advanced in the development phase, with current activities focused on optimisation of assay performance and system integration, as well as preparations for subsequent validation activities. Subject to successful completion of development, and regulatory processes, a commercial launch is currently targeted for the second half of 2027.

Upon launch, the assay will be distributed through the partner’s global sales and distribution network, providing Gentian with broad international market access and reinforcing its commitment to scalable, high-quality diagnostic solutions.

This project builds on Gentian’s growing portfolio of successfully commercialized biomarker assays and further solidifies its reputation as a trusted development and manufacturing partner for global diagnostic leaders.

“We are pleased to see this project advancing into the later stages of development in close collaboration with a global diagnostics leader,” says Matti Heinonen, CEO of Gentian Diagnostics. “The agreement reflects confidence in our assay development capabilities and supports our strategy of creating long-term value through strategic partnerships in the global diagnostics market.”

[Boms]

Vanskelig øvelse å begynne å regne på verdiene disse meldingen kan generere om det lykkes. Så selskapet må i mitt hode vurderes etter nåværende businessen som jo har hatt en god trend, også får vi bare lage oss en forhåpning om hvor bra dette produktet kan bli.

En ganske håpløs øvelse, men mitt inntrykk av management nå er at det jobbes seriøst med både den løpende driften og også NT-proBNP.

[TekBot]

Gentian Diagnostics: Invitation to presentation of fourth quarter results

Gentian Diagnostics ASA will present its fourth quarter 2025 results on 11 February 2026 at 09.00 CEST.

The presentation will be held as a live webcast on the company’s website: Gentian Diagnostic - Investor presentations
…

Vis børsmeldingen

The webcast will be hosted by representatives from the Gentian Diagnostics management. A recording will be available on the company website after the presentation.

Kilde

[TekBot]

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the fourth quarter of 2025.
…

Vis børsmeldingen

Highlights include:
Record sales of NOK 46.6 million in 4Q25, up 9% vs 4Q24 (12% organic growth). Full year 2025 sales of NOK 176.5 million up 16% (17% organic growth) vs 2024.

EBITDA of NOK 10.5 million in 4Q25 vs NOK 8.1 million in 4Q24. For the full year of 2025 the EBITDA was NOK 34.6 million vs 24.7 million in 2024 (+40%). The EBITDA for 2025 includes NOK 13.3 million (NOK 12 million) in pipeline development expenses.

Improved gross margin to 58% (56%) in 4Q25 and to 56% in 2025 versus 54% in 2024.

Sales of Cystatin C increased with 22% in 4Q25 compared to 4Q24, and by 32% for the full year 2025 versus 2024, driven by strong performance in the US.

Sales of fCAL turbo decreased with 6% in 4Q25 compared to 4Q24, and by 1% for the full year 2025 versus 2024, due to unusual high stock building in 4Q24.

Sales to the US were NOK 29.4 million in 2025 vs NOK 12.2 million in 2024. New accounts and growth in existing accounts both contributed to increased revenues. The warehouse shift for one of our largest customers accounts for about NOK 11.3 million of the 2025 revenue.

Very recent testing shows that the current assay version of NT-proBNP does not perform reliably in the lower measurement range. The company has therefore initiated activities to investigate whether redesigning the assay could improve robustness, with initial results to be shared once available. The company expects to present revised development timelines during Q2 2026.

Gentian announced an exclusive partnership with a top global diagnostics company to develop a new assay that will be incorporated into one of the world’s most widely used clinical chemistry analyser platforms.

The board proposes a dividend of NOK 0.60 per share based on a solid cash position and sound underlying earnings with current growth opportunities fully financed.

Webcast
The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company’s website:

Gentian Diagnostic - Investor presentations

The webcast will also be available on the company website after the presentation.

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business controller at Gentian Diagnostics ASA, on 11 February 2025 at 08:20 CET.

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

Kilde

[TekBot]

Update on the development of the NT-proBNP assay

Moss, 11 February 2026

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations have confirmed that the current assay version does not demonstrate sufficiently robust performance in the lower concentration ranges, particularly around clinically important cut off levels.
…

Vis børsmeldingen

Based on these findings, Gentian has identified several measures that may enhance assay performance; however, these require a redesign of the test. The company has therefore initiated activities to investigate whether redesigning the assay could improve robustness, with initial results to be shared once available.

At the present stage, Gentian is not able to provide a reliable updated timeline for the release of the Research Use Only (RUO) product nor for the subsequent commercial launch of the NT proBNP assay. The company expects to present revised development timelines during Q2 2026. Consequently, the planned NT proBNP webcast will also be postponed.

Commenting on the development, Gentian CEO Matti Heinonen said:
“This is certainly a disappointing development and a setback for the project. As the assay did not meet the performance requirements needed to pass the verification stage, we have decided to return the project to the optimisation phase. This approach carries a higher level of development risk, but it is necessary as we now evaluate whether a redesigned assay can deliver a viable and commercially relevant NT proBNP product.”

For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

Kilde

[Savepig]

Blandet drops. Fortsatt vekst og utbytte, men problemer med r&d

[Haltopen]

Heldigvis går butikken som den skal, men selvfølgelig svært skuffende med utviklingen av NT-proBNP. Tilbake til optimiseringsfasen.

Da er det sannsynligvis markøren som utvikles sammen med den eksklusive partneren som blir neste på markedet. Launch H2 2027 betyr vi bør få mer konkret informasjon ila 2026.

[Haltopen]

DnB: To reflect the delay and uncertain outcome of the project, we remove NT-proBNP from our estimates, leaving the project as potential upside. Consequently, despite solid sales growth from existing products, we reduce our 2026–30e sales and our target price to NOK63 (67), but still find Gentian attractively valued and reiterate our BUY

[TekBot]

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026

The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per
…

Vis børsmeldingen

share, based on the company’s financial statements for the financial year 2025,
to the General Meeting.

Dividend amount: 0.60 per share
Announced currency: Norwegian krone (NOK)
Last day including right: 5 May 2026
Ex-date: 6 May 2026
Record date: 7 May 2026
Payment date: from 18 May 2026
Date of approval: 5 May 2026

For further information, please contact:

Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TraderJoe]

Skal si det tilbys rabatt etter en helt grei (minus) kvartalsrapport. Tydelig at noen skal ut, koste hva det koste vil

[Savepig]

616 millioner for gentian kjennes ikke superdyrt ut, det går an å si

[TraderJoe]

Ser jo litt ut som tvangssalg - måten det selges på…

[TekBot]

Mandatory notification of trade

Moss, 12 February 2026

Gentian Diagnostics ASA (“Gentian”) has today been notified that the following transaction has been completed by a primary insider in Gentian:
…

Vis børsmeldingen

Njaal Kind, Chief Financial Officer and primary insider in Gentian, has purchased 3,000 shares in Gentian at NOK 40.00 per share. Mr. Kind owns 29,128 shares and 140,670 options after this transaction.

PDMR notification pursuant to the EU Market Abuse Regulation Article 19 is attached.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II.

For further information, please contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25

Kilde

[Savepig]

Ja enig

[Haltopen]

Det bør kommer flere slike meldinger i dag…

[TraderJoe]

Er ikke utenkelig at det er Runar Vatne som tvangsselges her. Han har jo slitt betydelig de siste årene…

Han er jo største aksjonær gjennom Vatne Equity og Lioness… Dette er siste aksjene han han sitter med i børsnoterte selskapet, etter hva jeg kan se

[Do2Do]

Kan være. Men det er flere som har solgt en del i 2026 som har igjen volum nok: Sæther, Voldberg, Rasmussen gruppen, samt Delphi og DNB fond.

Vi får vel svaret i morgen om salgspresset fortsetter - evt mandag kveld på lister.

600 m markedsverdi, 106 m cash, snitt 23% årlig salgsvekst over flere år, estimerer 60-80 m EBITDA i år (dersom ikke de driter seg ut igjen - med Q2 i minne), så er det vel lite grunn til å selge nå, om man ikke må.

[Savepig]

Fremdeles ikke en billig aksje, men ikke like crazy som før

Edit: screenshot fra quartr, har ikke hatt tid til å plotte mitt eget regneark i dag

[tooeasy891]

Tror du må tweake den AI-en din litt.
ev/ebitda er 14,45, ikke 17,9.

[Do2Do]

@Savepig

Fremdeles ikke en billig aksje

Det er ikke Orkla du ser på

Snitt 23 % årlig vekst, 17% siste år…
Og god kostnadskontroll hele veien